Myeloma News and Research RSS Feed - Myeloma News and Research

Findings reveal variations between countries and regions in use of HSCT procedure

Findings reveal variations between countries and regions in use of HSCT procedure

Since the first experimental bone marrow transplant over 50 years ago, more than one million hematopoietic stem cell transplantations (HSCT) have been performed in 75 countries, according to new research charting the remarkable growth in the worldwide use of HSCT, published in The Lancet Haematology journal. [More]
New NCCN Guidelines for treating Acute Lymphoblastic Leukemia

New NCCN Guidelines for treating Acute Lymphoblastic Leukemia

According to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Acute Lymphoblastic Leukemia (ALL), the treatment approach to ALL is one of the most complex and intensive programs in cancer therapy. [More]
Study provides new insights into early events that shape cancer

Study provides new insights into early events that shape cancer

A study led by researchers from Brigham and Women's Hospital suggests a new way to trace cancer back to its cell type of origin. By leveraging the epigenome maps produced by the Roadmap Epigenomics Program - a resource of data collected from over 100 cell types - the research team found that the unique genetic landscape of a particular tumor could be used to predict that tumor's cell type of origin. [More]
President of MD Anderson selected as new fellow of AACR Academy

President of MD Anderson selected as new fellow of AACR Academy

Ron DePinho, M.D., president of The University of Texas MD Anderson Cancer Center, will be inducted as a new fellow of the American Association for Cancer Research Academy. He joins 10 other cancer leaders in the prestigious academy that recognizes people who have made significant contributions to cancer research. [More]
Biotech investor invests in InterCure to increase stake in XTL Biopharmaceuticals

Biotech investor invests in InterCure to increase stake in XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that Israeli biotech investor Alex Rabinovich, its largest shareholder, increased his stake in the Company through his investment in InterCure, an XTL subsidiary, and recent purchases of XTL stock in the market. [More]
Harmless plant extract can help treat Cushing Disease

Harmless plant extract can help treat Cushing Disease

Cushing Disease, not to be confused with Cushing's Syndrome, is caused by a tumour in the pituitary gland in the brain. The tumour secrets increased amounts of the stress hormone adrenocorticotropin (ACTH) followed by cortisol release from the adrenal glands leading to rapid weight gain, elevated blood pressure and muscular weakness. [More]
Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Jazz Pharmaceuticals plc announced today that researchers will present data on the use of defibrotide, an investigational medicine being studied in the United States (U.S.) for the treatment of hepatic veno-occlusive disease (VOD), a rare, potentially life-threatening, early complication in patients undergoing hematopoietic stem-cell transplantation (HSCT) therapy. [More]
InterveXion receives federal grants for development of drug therapies to treat methamphetamine users

InterveXion receives federal grants for development of drug therapies to treat methamphetamine users

A University of Arkansas for Medical Sciences BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break their addiction. [More]
Leukemia & Lymphoma Society announces launch of new partnership to empower people with lymphoma

Leukemia & Lymphoma Society announces launch of new partnership to empower people with lymphoma

The Leukemia & Lymphoma Society together with the Lymphoma Research Foundation, CancerCare, the Association of Community Cancer Centers and Genentech announced the launch of a new partnership, the Alliance for Resource Collaboration in Hematology (ARCH). [More]
Damon Runyon Cancer Research Foundation names 15 new Damon Runyon Fellows

Damon Runyon Cancer Research Foundation names 15 new Damon Runyon Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 15 new Damon Runyon Fellows at its fall Fellowship Award Committee review. The recipients of this prestigious, four-year award are outstanding postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators across the country. [More]
FDA’s approval of ibrutinib to treat Waldenstrom's macroglobulinemia receives praises from LLS

FDA’s approval of ibrutinib to treat Waldenstrom's macroglobulinemia receives praises from LLS

The U.S. Food and Drug Administration approval of ibrutinib (Imbruvica) to treat patients with Waldenstrom's macroglobulinemia(WM) is a significant advance for patients with this rare blood cancer. [More]
Researchers turn clinical experience in multiple myeloma treatment into instructive review for physicians

Researchers turn clinical experience in multiple myeloma treatment into instructive review for physicians

Multiple myeloma is a malignant disease characterised by proliferation of clonal plasma cells in the bone marrow and typically accompanied by the secretion of monoclonal immunoglobulins that are detectable in the serum or urine. Increased understanding of the microenvironmental interactions between malignant plasma cells and the bone marrow niche, and their role in disease progression and acquisition of therapy resistance, has helped the development of novel therapeutic drugs for use in combination with cytostatic therapy. [More]
New research helps explain why pancreatic cancer is so lethal

New research helps explain why pancreatic cancer is so lethal

New research from the University of Michigan Comprehensive Cancer Center helps explain why pancreatic cancer is so lethal, with fewer than a third of patients surviving even early stage disease. [More]
CAR T-cell therapy enters into Phase I clinical trial

CAR T-cell therapy enters into Phase I clinical trial

Cancer fighting chimeric antigen receptor (CAR) T cells, developed in the Sentman laboratory of Dartmouth's Norris Cotton Cancer Center, are taking the next step into a Phase I clinical trial beginning early in 2015. [More]
Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Aptose begins APTO-253 clinical study in patients with relapsed or refractory hematologic malignancies

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced dosing of the first patient in its Phase 1b clinical study of APTO-253 in patients with relapsed or refractory hematologic malignancies. [More]
BioLight invests in newly-formed ophthalmic company

BioLight invests in newly-formed ophthalmic company

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced its investment in a newly-formed ophthalmic company that has licensed-in a world-wide drug-delivery platform from the Hebrew University, Israel, that has the potential to enable more efficient and safer delivery of eye drops. [More]
Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics, Inc. today announced that it has been awarded BayBio's 2014 Pantheon DiNA Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA (ibrutinib). The award was presented at BayBio's 11th Annual Pantheon DiNA Awards ceremony in San Francisco. [More]
Drugs delay disease progression for women with hormone-receptor-positive metastatic breast cancer

Drugs delay disease progression for women with hormone-receptor-positive metastatic breast cancer

A new combination of cancer drugs delayed disease progression for patients with hormone-receptor-positive metastatic breast cancer, according to a multi-center phase II trial. The findings of the randomized study (S6-03) were presented at the 2014 San Antonio Breast Cancer Symposium, held Dec. 6-9, by Kerin Adelson, M.D., assistant professor of medical oncology at Yale Cancer Center and chief quality officer at Smilow Cancer Hospital at Yale-New Haven. [More]
IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL). [More]
Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p). [More]